Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -14% Improvement Relative Risk c19hcq.org Salehi et al. HCQ for COVID-19 ICU PATIENTS Is very late treatment with HCQ beneficial for COVID-19? Retrospective 125 patients in Iran (April - September 2021) No significant difference in mortality Salehi et al., Research Square, doi:10.21203/rs.3.rs-1362678/v1 Favors HCQ Favors control
Risk factors of death in mechanically ventilated COVID-19 patients: a retrospective multi-center study
Salehi et al., Research Square, doi:10.21203/rs.3.rs-1362678/v1 (Preprint)
Salehi et al., Risk factors of death in mechanically ventilated COVID-19 patients: a retrospective multi-center study, Research Square, doi:10.21203/rs.3.rs-1362678/v1 (Preprint)
Mar 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 125 mechanically ventilated ICU patients in Iran, showing no significant difference with HCQ treatment in unadjusted results. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 14.5% higher, RR 1.14, p = 0.44, treatment 53 of 86 (61.6%), control 21 of 39 (53.8%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Salehi et al., 11 Mar 2022, retrospective, Iran, preprint, mean age 62.0, 11 authors, study period April 2021 - September 2021.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Risk factors of death in mechanically ventilated COVID-19 patients: a retrospective multi- center study Mohammadreza Salehi Department of Infectious Disease, Imam Khomeini Hospital complex, Tehran University of Medical Sciences Mohammad-Taghi Beig Mohammadi Department of Anesthesiology & critical care, Imam Khomeini Hospital complex, Tehran University of Medical Sciences Seyed Hamidreza Abtahi Department of pulmonary and critical care medicine, Thoracic Research Center, Imam Khomeini Hospital complex, Tehran University of Medical Sciences, Tehran. Iran Samrand-Fattah Ghazi Department of Anesthesiology & critical care, Imam Khomeini Hospital complex, Tehran University of Medical Sciences Abolfazl Sobati Department of nursing and midwifery, Tehran University of Medical Sciences. Clinical Nurse, Imam Khomeini Hospital Complex, Tehran, Iran Rama Bozorgmehr Shohada-e Tajrish Hospital, Shahid Beheshti University of Medical Sciences Seyed Ali Dehghan Manshadi Department of Infectious Disease, Imam Khomeini Hospital complex, Tehran University of Medical Sciences Saeed Reza Jamali Siahkali Department of Infectious Disease, Ziaeian Hospital, Tehran University of Medical Sciences Mostafa Mohammadi Department of Anesthesiology & critical care, Imam Khomeini Hospital complex, Tehran University of Medical Sciences Banafsheh Moradmand Badie Australasian Bone Marrow Transplant Recipient Registry (ABMTRR), Sydney, Australia Ensiyeh Rahimi (  ensiyehrahimi@gmail.com ) Department of Infectious Disease, Imam Khomeini Hospital complex, Tehran University of Medical Sciences Page 1/22 Research Article Keywords: COVID-19, mechanical ventilation, extubation, mortality risk factors Posted Date: March 11th, 2022 DOI: https://doi.org/10.21203/rs.3.rs-1362678/v1 License:   This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 2/22 Abstract Introduction: Despite the improvement in COVID-19 therapeutic management the mortality of mechanically ventilated COVID-19 patients remains high. In this study, we determined risk factors of mortality in these cases. Methods: This retrospective study examined clinical and paraclinical data of COVID-19 patients mechanically ventilated at the time of hospitalization to ICU admission until death or discharge from hospital between April and September in 2021 in three COVID-19 referral hospitals. Results: One hundred twenty-five patients (60% male, mean age 62 ± 15.18, range 17 to 97 years old) were recruited to this study. 51(40%) survived and 74 (60%) didn’t survive. At the time of hospital admission, the vital signs were not significantly different between the survivors and non-survivors groups, also diarrhea was not reported in non-survivors, but reported in 9.5% of survivors (P = 0.02). The mean age of 74 non-survivors was higher than 51 survivors (65.1 ± 14.17 vs 56.9 ± 15.41, P = 0.003). The intubation time since the patients were admitted to hospitals was not significantly different between the two groups (3.38 ± 2.88 days vs 4.16 ± 3.42 days, P = 0.34). The mean LDH and D-dimer at the time of ICU admission were significantly higher in the non-survivors group (863 ± 449 vs 613 ± 326, P = 0.01; 4081 ± 3342 vs 542 ± 634, P = 0.009; respectively). However, the mean CRP was not significantly different between the two groups (76 ± 66.4, 54 ± 84.3; P = 0.1). Mean APACHE-II score was higher in the non-survivors than the survivors (15 vs 13; P = 0.01). Use of remdesivir,..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit